Russell Investments Group Ltd. Has $1.67 Million Stake in Integra LifeSciences Holdings Corporation $IART

Key Points

• Russell Investments Group Ltd. reduced its stake in Integra LifeSciences Holdings Corporation by 30.3%, selling 32,970 shares and maintaining 75,920 shares valued at $1,669,000.
• Integra's stock recently rose 3.4%, with a current trading price of $14.76 and a market cap of $1.15 billion, despite a challenging financial quarter with revenue down 0.6% year-over-year.
• Analysts have lowered their price targets for Integra LifeSciences, with Wells Fargo reducing its target from $25 to $13, indicating a more cautious outlook for the company's shares.

Russell Investments Group Ltd. decreased its stake in Integra LifeSciences Holdings Corporation (NASDAQ:IART - Free Report) by 30.3% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 75,920 shares of the life sciences company's stock after selling 32,970 shares during the quarter. Russell Investments Group Ltd. owned approximately 0.10% of Integra LifeSciences worth $1,669,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Principal Financial Group Inc. lifted its position in shares of Integra LifeSciences by 2.5% in the first quarter. Principal Financial Group Inc. now owns 433,924 shares of the life sciences company's stock valued at $9,542,000 after acquiring an additional 10,492 shares in the last quarter. Wealth Enhancement Advisory Services LLC acquired a new stake in shares of Integra LifeSciences in the first quarter valued at approximately $251,000. Victory Capital Management Inc. increased its holdings in shares of Integra LifeSciences by 1,067.6% in the first quarter. Victory Capital Management Inc. now owns 147,982 shares of the life sciences company's stock valued at $3,254,000 after purchasing an additional 135,308 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Integra LifeSciences by 3.9% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 38,466 shares of the life sciences company's stock worth $872,000 after acquiring an additional 1,437 shares during the period. Finally, GAMMA Investing LLC grew its position in Integra LifeSciences by 3,595.1% in the first quarter. GAMMA Investing LLC now owns 23,353 shares of the life sciences company's stock worth $5,140,000 after acquiring an additional 22,721 shares during the period. Institutional investors and hedge funds own 84.78% of the company's stock.

Analyst Ratings Changes

Several research analysts have recently commented on IART shares. JMP Securities lowered their price target on Integra LifeSciences from $35.00 to $25.00 and set a "market outperform" rating for the company in a research report on Friday, May 9th. Wells Fargo & Company dropped their target price on Integra LifeSciences from $25.00 to $13.00 and set an "equal weight" rating on the stock in a research report on Tuesday, May 6th. Finally, JPMorgan Chase & Co. reduced their target price on Integra LifeSciences from $24.00 to $12.00 and set an "underweight" rating on the stock in a research note on Tuesday, May 6th. Two analysts have rated the stock with a Buy rating, three have issued a Hold rating and four have assigned a Sell rating to the company's stock. According to MarketBeat.com, Integra LifeSciences presently has a consensus rating of "Reduce" and a consensus target price of $18.43.

Integra LifeSciences Stock Performance

NASDAQ IART traded up $0.29 during trading hours on Friday, reaching $15.13. The company's stock had a trading volume of 1,189,457 shares, compared to its average volume of 1,475,275. The business has a 50-day simple moving average of $13.05 and a 200 day simple moving average of $16.08. Integra LifeSciences Holdings Corporation has a 52 week low of $11.06 and a 52 week high of $27.13. The stock has a market cap of $1.18 billion, a PE ratio of -2.32, a PEG ratio of 0.84 and a beta of 1.16. The company has a current ratio of 1.23, a quick ratio of 0.73 and a debt-to-equity ratio of 1.18.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last announced its quarterly earnings results on Thursday, July 31st. The life sciences company reported $0.45 EPS for the quarter, beating the consensus estimate of $0.43 by $0.02. Integra LifeSciences had a negative net margin of 30.87% and a positive return on equity of 12.15%. The company had revenue of $415.61 million for the quarter, compared to analyst estimates of $395.06 million. During the same quarter last year, the business earned $0.63 earnings per share. Integra LifeSciences's revenue was down .6% compared to the same quarter last year. Integra LifeSciences has set its FY 2025 guidance at 2.190-2.290 EPS. Q3 2025 guidance at 0.400-0.450 EPS. Equities research analysts predict that Integra LifeSciences Holdings Corporation will post 2.45 earnings per share for the current fiscal year.

Integra LifeSciences Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.